Sensei Biotherapeutics Announces Conference Presentations
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical-stage firm dedicated to innovating next-generation therapies for cancer patients, has exciting news. The company is set to present at two prominent scientific conferences that will spotlight its groundbreaking work.
Highlighted Conference: PEGS Europe
The first notable event is the PEGS Europe: Protein and Antibody Engineering Summit, happening from November 5-7. This prestigious summit will take place in Barcelona, Spain, and will feature a range of insightful discussions and presentations pertinent to the field.
Presentation Details
Sensei Biotherapeutics will present an intriguing topic: Selectively Targeting VISTA in the Tumor Microenvironment with SNS-101, a Conditionally Active Monoclonal Antibody. The session will be led by Edward van der Horst, Ph.D., the Chief Scientific Officer. He will dive into the details during the Antibody-Based Cancer Therapies session scheduled for Tuesday, November 5 at 9:00 a.m. CET.
Annual Meeting of the Society for Immunotherapy Cancer
The second significant opportunity for Sensei Biotherapeutics arises at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting, set to take place between November 6-10. This meeting will be hosted in Houston, Texas.
Another Key Presentation
At this meeting, the company will showcase its research on Spatial Proteomic Profiling of VISTA and PSGL-1 Interactions Across Cancer Indications. The presentation, by F. Donelson Smith, Ph.D., the Senior Director for Biologics Discovery and Early Development, will incorporate a poster format. Attendees can catch it on Saturday, November 9, during two time slots: from 12:15–1:45 p.m. and again from 7:00-8:30 p.m. CST at the George R. Brown Convention Center.
About Sensei Biotherapeutics
Sensei Biotherapeutics is at the forefront of cancer treatment innovation. Their TMAb™ platform focuses on developing conditionally active therapeutics aimed at counteracting immunosuppressive signals present in cancerous environments. The lead candidate, SNS-101, has been specifically engineered to inhibit the VISTA checkpoint selectively around tumor sites where immun suppression occurs.
The company is also advancing other promising candidates including SNS-102, targeting VSIG-4; SNS-103, focusing on CD39; and SNS-201, a bispecific antibody that aims to dual-action against both VISTA and CD28. With these innovative developments, Sensei Biotherapeutics is committed to providing cutting-edge solutions for cancer therapy.
Stay Connected with Sensei Biotherapeutics
For further insights into their innovative therapies and upcoming events, visit www.senseibio.com. You can also engage with them on X @SenseiBio and find them on LinkedIn.
Contact Information
Those interested in learning more should reach out to: Michael Biega, Senior Director of Investor Relations at Sensei Biotherapeutics via mbiega@senseibio.com.
Additionally, for media inquiries, please contact Joyce Allaire at LifeSci Advisors through Jallaire@lifesciadvisors.com.
Frequently Asked Questions
What is the focus of Sensei Biotherapeutics?
Sensei Biotherapeutics focuses on developing next-generation therapeutics for cancer patients utilizing innovative technologies.
When and where will the PEGS Europe conference take place?
The PEGS Europe summit will occur from November 5-7, 2024, in Barcelona, Spain.
Who is presenting at the Society for Immunotherapy Cancer meeting?
F. Donelson Smith, Ph.D., will present at the SITC annual meeting focusing on VISTA and PSGL-1 interactions.
What are Sensei's investigational candidates?
Some of the investigational candidates include SNS-101, SNS-102, SNS-103, and SNS-201, each targeting different aspects of cancer biology.
How can I keep up with Sensei Biotherapeutics?
You can visit their website at www.senseibio.com or follow them on social media platforms like LinkedIn and Twitter.
